IndieBio
IndieBio is an accelerator firm established in 2014 and based in San Francisco, California, with an additional office in New York. It specializes in startups that utilize synthetic biology to address significant global challenges. IndieBio runs four-month accelerator programs aimed at both companies and teams with innovative ideas, focusing on seed-stage and early-stage investments. The firm typically invests $250,000, providing $50,000 in exchange for eight percent equity in biotech startups, with the possibility of an additional $25,000 as a convertible loan note. IndieBio prioritizes investments in businesses that leverage biology as the core of their technology, particularly in life sciences, biotechnology, and related fields. The firm favors teams with a minimum of two co-founders and is open to investing in startups from various geographical locations.
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.
Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.
Oralta is a U.S.-based company that specializes in the manufacture of probiotic supplements aimed at improving oral health. Its flagship product, FRESH BREATH, consists of chewable tablets designed to combat bad breath by eliminating odor-causing bacteria while promoting the growth of beneficial probiotic strains. The tablets work by preventing the buildup of harmful germs, reducing their growth, and inactivating the byproducts responsible for unpleasant odors. Oralta's innovative approach focuses on restoring a healthy balance of oral bacteria, ultimately enhancing overall oral hygiene and addressing conditions such as tooth decay and gum disease.
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.
Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.
Dahlia Biosciences specializes in the fields of biotechnology and DNA analysis and diagnostics. The company provides a single-cell RNA analysis tools for research and diagnostic applications. Dahlia Biosciences was founded in 2011 and headquartered in California, United States.
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.
Oralta is a U.S.-based company that specializes in the manufacture of probiotic supplements aimed at improving oral health. Its flagship product, FRESH BREATH, consists of chewable tablets designed to combat bad breath by eliminating odor-causing bacteria while promoting the growth of beneficial probiotic strains. The tablets work by preventing the buildup of harmful germs, reducing their growth, and inactivating the byproducts responsible for unpleasant odors. Oralta's innovative approach focuses on restoring a healthy balance of oral bacteria, ultimately enhancing overall oral hygiene and addressing conditions such as tooth decay and gum disease.
Dahlia Biosciences specializes in the fields of biotechnology and DNA analysis and diagnostics. The company provides a single-cell RNA analysis tools for research and diagnostic applications. Dahlia Biosciences was founded in 2011 and headquartered in California, United States.
Mouth2Mouth is a healthcare startup that develops personalized probiotics for oral health. Based on microbiome data from thousands of healthy individuals, their AI-driven platform determines consortia of beneficial bacteria that fight widespread conditions such as tooth decay, gum disease, and bad breath. The company is on a mission to improve oral hygiene and provide a solution to oral diseases by use of an all-natural process.
Dahlia Biosciences specializes in the fields of biotechnology and DNA analysis and diagnostics. The company provides a single-cell RNA analysis tools for research and diagnostic applications. Dahlia Biosciences was founded in 2011 and headquartered in California, United States.
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.